Previous studies from Multhoff and colleagues reported that plasma membrane Hsp70 acts as a tumour-specific recognition structure for activated NK cells, and that the incubation of NK cells with Hsp70 and/or a 14-mer peptide derived from the N-terminal sequence of Hsp70 (TKDNNLLGRFELSG, TKD, aa 450-463) plus a low dose of IL-2 triggers NK cell proliferation and migration, and their capacity to kill cancer cells expressing membrane Hsp70. Herein, we have used flow cytometry to determine the influence of in vitro stimulation of peripheral blood mononuclear cells from healthy individuals with IL-2 or IL-15, either alone or in combination with TKD peptide on the cell surface expression of CD94, NK cell activatory receptors (CD16, NK2D, NKG2C, NKp30, NKp44, NKp46, NKp80, KIR2DL4, DNAM-1 and LAMP1) and NK cell inhibitory receptors (NKG2A, KIR2DL2/L3, LIR1/ILT-2 and NKR-P1A) by CD3+CD56+ (NKT), CD3+CD4+, CD3+CD8+ and CD19+ populations. NKG2D, DNAM-1, LAMP1 and NKR-P1A expression was upregulated after the stimulation with IL-2 or IL-15 alone or in combination with TKD in NKT, CD8+ T cells and B cells. CD94 was upregulated in NKT and CD8+ T cells. Concurrently, an increase in a number of CD8+ T cells expressing LIR1/ILT-2 and CD4+ T cells positive for NKR-P1A was observed. The proportion of CD8+ T cells that expressed NKG2D was higher after IL-2/TKD treatment, when compared with IL-2 treatment alone. In comparison with IL-15 alone, IL-15/TKD treatment increased the proportion of NKT cells that were positive for CD94, LAMP1 and NKRP-1A. The more potent effect of IL-15/TKD on cell surface expression of NKG2D, LIR1/ILT-2 and NKRP-1A was observed in B cells compared with IL-15 alone. However, this increase was not of statistical significance. IL-2/TKD induced significant upregulation of LAMP1 in CD8+ T cells compared with IL-2 alone. Besides NK cells, other immunocompetent cells present within the fraction of peripheral blood mononuclear cells were influenced by the PLOS ONE |
Introduction
Previous studies from Multhoff and colleagues have reported the selective expression of membrane form of the 70 kDa heat shock protein Hsp70 on tumour cells, including leukaemia blasts, but not on corresponding non-malignant tissues or non-transformed cells [1, 2, 3] . Moreover, a membrane Hsp70 positive tumor phenotype has been found to be associated with a significantly decreased overall survival in patients with lower rectal and lung carcinomas [4] . Plasma membrane Hsp70 was demonstrated to act as a tumor-specific recognition structure for pre-activated NK cells expressing high amounts of CD94. Furthermore, Hsp70 plasma membrane expression correlates with an increased sensitivity to allogeneic NK cells [2, 5] . The epitope recognized by cmHsp70.1 monoclonal antibody, 8-mer peptide NLLGRFEL (NLL, comprising amino acids 454-461), was found to be localized within C-terminal substrate binding domain of the inducible Hsp70 molecule exposed to the extracellular milieu of tumors [6, 7] . Multhoff et al. [8] demonstrated that similar to full-length Hsp70 protein, the N-terminalextended 14-mer peptide TKDNNLLGRFELSG (TKD, aa 450-463) was able to stimulate the cytolytic and proliferative activity of NK cells at concentrations equivalent to full-length Hsp70 protein. Gastpar et al. [9] previously shown that the incubation of lymphocytes with Hsp70-derived peptide TKD in the presence of a low dose of IL-2 results in an enhanced cytolytic and migratory capacity of NK cells toward Hsp70 membrane-positive tumor cells in vitro and in a xenograft tumor mouse model [10] . In a clinical phase I trial, the tolerability, feasibility, and safety of adoptively transferred, autologous IL-2/TKD-activated NK cells have been shown in patients having colorectal and lung carcinoma [4, 11] .
We have recently reported the effect of in vitro stimulation with IL-2 or IL-15 alone or in combination with Hsp70 derived 14-mer peptide (TKD) on cell surface expression of NK activatory and inhibitory receptors in CD3 -CD56 + cellular population within peripheral blood mononuclear cells of healthy individuals [12] . The cell surface expression profile of the following activatory receptors was studied using flow cytometry: a low affinity receptor for aggregated IgG (CD16), members of NKG2 natural killer cell receptor family (NKG2D/CD314 and NKG2C associating with CD94 to form a heterodimer), members of the natural cytotoxicity receptor (NCR) family (NCR1/NKp46, NCR2/NKp44 and NCR3/NKp30), a killer cell immunoglobulin-like receptor (KIR2DL4/CD158d), a killer cell lectin-like receptor subfamily F, member 1 (KLRF1/NKp80), DNAX accessory molecule-1 (DNAM-1/CD226) and lysosomeassociated membrane protein-1 (LAMP1/CD107a) [12] . Additionally, the cell surface expression of the following NK cell inhibitory receptors was determined: NKG2A creating a complex with CD94 molecule, a killer cell immunoglobulin-like receptor (KIR2DL2/L3/CD158b, NKAT2), a member of the leukocyte immunoglobulin-like receptor (LIR) family such as the immunoglobulin-like transcript 2 (LIR1/ILT-2/CD85j) and a killer cell lectin-like receptor subfamily B, member 1 (KLRB1) also known as NKR-P1A/CD161 [12] . Both, NK activatory (CD94, NKG2D, NKp44, NKp30, KIR2DL4, DNAM-1, LAMP1) and NK inhibitory receptors (NKG2A and NKR-P1A) were upregulated after the stimulation with IL-2 or IL- 15 [13] . Maturity-driven NK receptor expression on non-NK cell type is influenced by multiple factors including viral infections and particular microenviromental conditions [13, 14] . These receptors may exert an inhibitory activity on T cell receptor-mediated functions and provide an important mechanism of down-regulation of T cell responses, which may be helpful for the maintenance of homeostasis, prevention of autoimmunity, but could be harmful to the host in certain chronic viral infections [14] . Moreover, the finding of NK inhibitory positive receptor immunoregulatory T cells at the tumor site and in the circulation of cancer patients may explain the dysfunction of T lymphocytes against cancer cells, which can cause escape of tumors from immunosurveillance. Significantly increased number of CD4 + NKR-P1A + T cells was detected in patients with diverse types of cancer and positively correlated with disease stage [15] . On the other side, lowered threshold for monocyte and B cell activation by decreasing inhibitory capacity through decreased LILRB1 expression helps promote inflammatory responses as CD8+ T cells become more difficult to activate [13] .
Cytokines are required to induce expression of NK receptors. It has been reported that in vitro stimulation with IL-2, IL-12 and IL-15 cytokines induced the expression of certain NK cell receptors (NKG2D, CD94/NKG2A) on T cells [16, 17] . It is also possible that the cytokines required for NK receptor expression may be produced, at least in part, by T cells themselves at given stages of activation [14] .
In the present study we determined the effect of in vitro stimulation using IL-2 and/or IL-15 alone or in combination with stress-inducible Hsp70 derived 14-mer peptide (TKD) on cell surface expression of NK cell activatory and inhibitory receptors in other cell populations within peripheral blood mononuclear cells of healthy individuals. The cell surface expression profile of the activatory and inhibitory receptors was studied in unstimulated and stimulated CD4 + T cells, CD8 + T cells, CD19 + B cells and CD3 + CD56 + NKT cells.
Materials and Methods
The study cohort consisted of 52 
Statistical analysis
Normality of the data was assessed using Shapiro-Wilk test, which indicated that our data did follow a normal distribution. Therefore, proportions of cells expressing an appropriate antigen and the amount of appropriate receptor expressed by cells of interest were compared between groups by parametric test (Student´s t-test) using SPSS Statistics software (version 21.0; IBM, Inc., USA).
Experimental data were expressed as column mean, error bars, vertical graphs. The upper and lower whiskers represent the mean ± the standard error of the mean (SEM). The mean is indicated by the line in each graph. (Fig 1) . While CD8 + T cells (mean 78.1%) and NKT cells (mean 40.6%) highly expressed NKR-P1A (NK inhibitory receptor), a moderate expression of NKR-P1A was detected on CD4 + T cells (mean 18.1%) and B cells (mean 9.2%) (Fig 2) .
The major NK activatory receptor NKG2D was highly expressed mainly on NKT cells (mean 70.4%), nevertheless NKG2D was also found on the cell surface of CD8 + T cells (mean (Fig 3) . While NKR-P1A (Fig 4) , NKG2D ( Fig 5) and CD94 (Fig 6) down-regulation occurred in both CD8 + T cells and NKT cells, LIR1/ILT-2 (Fig 7) and CD16 (Fig 8) down-regulation appeared entirely in CD8 + T cells. Further, NKG2A (Fig 9) exclusively expressed in NKT cells was also observed to be down-regulated when peripheral blood mononuclear cells had been cultured. Similarly, NKp80 (Fig 10) expressed in CD8 + T cells significantly decreased its cell surface expression during the culture of unstimulated peripheral blood mononuclear cells. On the other hand, LAMP1 (Fig 11) showed up-regulation in B cells and NKT cells. (Fig 4) . Nevertheless, an increase of the proportion of cells expressing DNAM-1 receptor was observed just in case of NKT, CD8 + T cells and B cells. CD4 + T cells, highly positive for DNAM-1, did not respond to IL-2 or IL-15 alone or in combination with TKD peptide (Fig 3) . NKG2D, the major NK cell activatory receptor, was also up-regulated in NKT, CD8 + T cells and B cells (Fig 5) . (Fig 11) . Moreover, the difference between IL-2 and IL-2/ TKD cell number positive for LAMP1 reached a statistical significance. CD94 cell surface expression differed before and after the stimulation with IL-2 or IL-15 alone or mixed with TKD peptide in NKT cells and CD8 + T cells (Fig 6) . Similarly, LIR1/ILT-2 cell surface expression changes were observed in CD8 + T cells (Fig 7) . The increase of the positive cell numbers for the tested marker was apparent after the treatment with the combination of low-dose IL-2 or IL-15 with or without TKD peptide when compared to unstimulated cells. Although the increase of the positive cell numbers for the tested marker was apparent after the treatment with the combination of low-dose IL-2 and TKD peptide when compared to IL-2 alone, it does not reach a statistical significance (NKG2D in CD8 + T cells) (Fig 5) . The effect of IL-15 with TKD peptide on the cell surface expression of appropriate receptors in particular cell subsets was more evident, but once again no statistical difference between IL-15 alone and IL-15/TKD stimulated cells was observed (NKR-P1A and CD94 in NKT cells; NKR-P1A in B cells) (Figs 4 and 6) . (Fig 20) .
Discussion
Previous findings suggest that membrane Hsp70 could serve as an unique immunotherapeutic target for a broad spectrum of tumor entities [18] . The functionality of human NK cells is regulated by interactions of numerous activatory, coactivatory and inhibitory receptors with specific ligands expressed by target cells [19] . NK cell unresponsiveness is under the dominant control of inhibitory receptors that bind with ubiquitously expressed MHC class I molecules.
On the other hand, NK cell activation and cytotoxicity is mediated by a deviation in the balance between inhibitory and activatory receptors in favour of activatory receptor signaling [20] . Previous studies of Multhoff group [1,2,3] identified a membrane-bound Hsp70 on tumor cells as a tumor-specific recognition structure for a perforin-independent, granzyme B-mediated and NKRP-1A). CD16, a low affinity IgG receptor, has been already reported to be expressed on monocytes, macrophages, neutrophils, mast cells and besides on NK cells, CD8+ T cells, and peripheral blood NKT-like cells [21, 22] , which we confirmed in this independent study. Our data are in agreement with the data of Romero et al. [23] who found that CD4+ resting peripheral blood lymphocytes did not express surface CD94, while CD8+ lymphocytes and NKT-like cells may be positive for CD94 [23, 24, 25] . As expected, we confirmed the presence of NKG2D receptor on unstimulated CD8+ T lymphocytes and NKT cells [26] and the absence of NKG2D receptor on unstimulated CD4+ T lymphocytes derived from healthy individuals [27, 28] . However, we observed a certain expression of NKG2D on unstimulated B lymphocytes as well. We were also able to identify NKG2C positivity on unstimulated NKT cells. Similarly, Lin et al. [29] who used α-GalCer stimulation as a method to obtain large numbers of NKT cells from human peripheral blood, showed the expression of NKG2C on purified NKT cells. DNAM-1/CD226 is constitutively expressed by most NK cells, T helper and cytotoxic T cells and a subset of B cells [30, 31] . These data are in compliance with our current findings. Nevertheless, we also observed a high expression of DNAM-1 on unstimulated NKT cells. In conformity with Kang N et al. and Kuylenstierna et al. we found no expression of KIR2DL2/L3 in unstimulated T cells and B cells [32, 33] and low expression in unstimulated NKT cells [34] . NKG2A receptor has been reported to be expressed in invariant NKT cells distributed preferentially in the liver [35, 36, 37] and maturing CD8 + T cells [13] . We could observe a moderate NKG2A expression in NKT cells present within the fraction of unstimulated peripheral blood mononuclear cells. NKRP-1A/CD161 is expressed on most unstimulated NK cells, subsets of CD4+ and CD8+ T cells and NKT cells [38, 39, 40] which is in line with our finding. Moreover, a moderate expression of NKRP-1A/CD161 on unstimulated B cells was detected in the course of the current study. Our data confirmed the results of the study of Kuttruff et al., who reported that unstimulated CD4+ T cells lacked surface NKp80 and detected NKp80 on a subset of CD8+ T cells at varying frequencies [41] . Compliant with the studies of Colonna et al. LIR1/ILT-2 expression was identified on unstimulated B cells and T lymphocytes [42] . IL-2 and IL-15 have similar biological properties in vitro, consistent with their shared receptor signalling components (IL-2/15βγ c ). However, specificity for IL-15 versus IL-2 is provided by unique private α-chain receptors that allow differential responsiveness depending on the ligand and high-affinity receptor expressed [43] .
The IL-2 stimulation of NK cells leads to a significant up-regulation of all NCRs and NKG2D receptors and to an increase in cytokine secretion, which is associated with enhanced cytotoxic activity against leukemic and tumor cells [44, 45, 46] . Therefore, immunotherapeutic trials with unstimulated and either ex vivo or in vivo IL-2-activated donor NK cells have focused on treating patients with high-risk malignancies in non-transplant settings and after haploidentical stem cell transplantation (haplo-SCT) [46] . However, limited data are available on the effect of IL-2 or IL-15 on other cell populations within in vitro, ex vivo or in vivo stimulated peripheral blood mononuclear cells.
Likewise Our data are consistent with Mingari et al., who observed the start of CD94 expression in T cells on day 4-6 after the addition of IL-2 or IL-15. Nevertheless, the maximum CD94 expression could be observed on day+10 of the culture [48] .
IL-15 and IL-2 up-regulate the expression and function of NKG2D [43, 49, 50] . Probably, as a consequence of this action we were able to observe up-regulation of NKG2D in NKT, CD8 + T cells and B cells. IL-15 functions as a key regulator of effector CTL activation and expansion by arming the NKG2D costimulatory pathway under inflammatory conditions [43, 49, 50, 51] .
Similarly, cytokine-induced killer cells, CD3+CD56+ terminally differentiated CD8 T cells, generated in vitro by stimulation of peripheral blood mononuclear cells or T-cell subsets with interferon-gamma, anti-CD3 and interleukin-2 have acquired NKG2D, but lack expression of most NK-specific activating (NKp30, NKp44, NKp46) and inhibitory (KIR2DL1, KIR2DL2, KIR3DL1, NKG2A) receptors [52] . Nevertheless, peripheral blood mononuclear cells expanded with IFN-γ, thymoglobulin and IL-2 have already been able to express additional NK activating/inhibitory receptors, such as NKp46, NKG2A, KIR2DL1 and KIR2DL2/DL3 [53] .
Our data acquired in the cohort of healthy individuals may be also partially supported by the study of Payne et al. who demonstrated that ex vivo stimulation of peripheral blood mononuclear cells of breast cancer patients with bryostatin 1 and ionomycin combined with IL-2, IL-7, and IL-15 could expand and activate CD25+ NKT and NK cells as well as T memory cells that displayed enhanced reactivity against HER-2/neu positive breast cancer in the presence of myeloid-derived suppressor cells. Ex vivo blockade experiments suggested that the NKG2D pathway might play an important role in overcoming MDSC suppression [54] .
LAMP-1/CD107a is a marker for degranulation of NK and activated CD8+ T cells [55] . It was developed as a method to quantitatively assess cytotoxicity of the NK cells and CTL (after overnight activation of PBMCs with IL-2) by measuring the expression of CD107α on the cell membrane, which appeared to be an effective and rapid screening test for cytotoxic defectsrelated diseases such as familial hemophagocytic lymphopro-liferative syndrome and other hemophagocytic lymphohistiocytosis secondary to primary immunodeficiency [56] . In our study, we observed an increased expression of LAMP-1/CD107a after IL-2 or IL-15 stimulation besides CD8 + T cells also on NKT and B cells.
While stimulation of peripheral blood mononuclear cells with IL-2/TKD combination led to the increased expression of NKG2D receptor in cytotoxic lymphocytes only compared to IL-2 alone, more potent effect of IL-15/TKD on peripheral blood mononuclear cell subpopulations was evident in comparison with IL-15 alone. The addition of TKD peptide caused the induction of cell surface expression of CD94, LAMP1 and NKRP-1A receptors in NKT cells and induction of cell surface expression of NKG2D, LIR1/ILT-2 and NKRP-1A receptors in B cells. Nevertheless, this increase has not yet reached a statistical significance.
Conclusion
In conclusion, the study demonstrated for the first time how other immunocompetent cells present within the fraction of peripheral blood mononuclear cells of healthy individuals that express CD94, NK cell activatory receptors and NK cell inhibitory receptors were influenced under in vitro conditions by the treatment with low-dose interleukins themselves or in combination with hsp70 derived (TKD) peptide enhancing NK cell cytotoxicity toward Hsp70 membrane-positive tumor cells.
